SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 273 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $3,025,000 | -89.8% | 41,900 | -76.6% | 0.72% | -95.7% |
| Q4 2017 | $29,516,000 | +148.8% | 179,200 | -5.9% | 16.65% | +170.4% |
| Q3 2017 | $11,862,000 | +148.3% | 190,400 | +217.3% | 6.16% | +171.0% |
| Q2 2017 | $4,778,000 | -34.6% | 60,000 | -41.6% | 2.27% | -44.4% |
| Q1 2017 | $7,306,000 | +327.0% | 102,800 | +81.0% | 4.09% | +367.6% |
| Q2 2016 | $1,711,000 | – | 56,800 | – | 0.87% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |